Sangamo Therapeutics and Astellas Collaborate on Innovative Gene Therapy for Neurological Diseases

FDA Clears IND for Arbor Biotechnologies’ ABO-101 Gene Editing Therapeutic for Primary Hyperoxaluria Type 1

Fortis Healthcare Acquires Stake in Agilus Diagnostics

FDA Approves BRAFTOVI® Combination Regimen as First-Line Treatment for BRAF V600E-Mutant Metastatic Colorectal Cancer

The Role of Big Data in Precision Medicine

Caris Life Sciences Celebrates 1,000+ Precision Medicine Studies, Advancing Cancer Research and Patient Outcomes

OncoHelix and Qualisure Diagnostics Partner to Bring Thyroid GuidePx® Test to Canadian Patients

Gates Foundation Invests $50 Million in Tessera Therapeutics to Advance Gene Therapy for Sickle Cell Disease

FDA Approves Ensartinib (Ensacove) as First-Line Treatment for ALK-Positive NSCLC

Guardant Health and Boehringer Ingelheim Collaborate to Advance Liquid Biopsy CDx for HER2-Targeted Therapy in NSCLC

Cartherics Receives $300K G-Rex Grant to Advance Cancer Cell Therapy Manufacturing

Roche Revolutionizes Mass Spectrometry Diagnostics with Launch of cobas® Mass Spec Solution

Complete Genomics Partners with Eurofins Clinical Enterprise to Expand Sequencing Service Offerings

NeuroKaire Secures $10M to Transform Precision Medicine in Psychiatry and Neurology

Redcliffe Labs Announces Leadership Transition to Drive Healthcare Accessibility

Home
/
update
/
details

AusperBio Completes $37 Million Series A Financing to Advance Targeted Oligonucleotide Therapies for HBV

NextEdge Admin

15 Jul 2024

2 min 56 sec

HBV,Viral Infection,Genetics,Hepatitis B,Targeted Delivery

AusperBio Therapeutics and Ausper Biopharma (collectively AusperBio), a clinical-stage biotechnology company, announced the completion of a $37 million Series A financing round. Led by existing investor InnoPinnacle Fund, new investors included Yuanbio Venture Capital, Qiming Venture Partners, Hankang Capital, and Genesis Capital.

The funding will support the clinical development of AusperBio's lead product, AHB-137, and further advance its proprietary Med-Oligo™ technology platform and product pipeline.

Dr. Guofeng Cheng, co-founder and CEO of AusperBio, expressed gratitude for the ongoing support from existing investors and welcomed new investors. He highlighted that this financing round marks a significant milestone, recognizing the company’s scientific and clinical achievements. With this funding and the recent Breakthrough Therapy Designation (BTD) from China's CDE, AusperBio is poised to expedite the clinical development of AHB-137, aiming to provide a vital new treatment option for CHB patients.

About AHB-137:

AHB-137 is a novel unconjugated antisense oligonucleotide (ASO) developed within AusperBio's proprietary Med-Oligo™ ASO technology platform, targeting a functional cure for chronic hepatitis B. Its preclinical and Phase 1 clinical data were highlighted at the 2023 and 2024 EASL™ conferences. Currently, AHB-137 is undergoing a Phase 1b trial across multiple international study sites and a concurrent Phase 2 trial in China. AusperBio’s global development strategy aims to rapidly advance AHB-137 towards the goal of an HBV cure.

About AusperBio:

AusperBio is a clinical-stage biopharmaceutical company with operations in the USA and China. The company focuses on advancing oligonucleotide and targeted delivery technologies for transformative therapies, particularly for curing chronic hepatitis B infection. Its proprietary Med-Oligo™ ASO platform enhances current ASO therapeutics through novel design insights. Combined with efficient targeted delivery conjugation technologies, the Med-Oligo™ Platform enables ASO therapeutics to treat a broad range of diseases, including viral infections, metabolic conditions, genetic disorders, and immune diseases.